Oramed Pharmaceuticals Stock Filter Stocks by Fundamentals
| ORMP Stock | USD 2.39 0.02 0.84% |
Oramed Pharmaceuticals fundamentals help investors to digest information that contributes to Oramed Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Oramed Stock. The fundamental analysis module provides a way to measure Oramed Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oramed Pharmaceuticals stock.
Oramed | Shares Owned by Institutions |
Oramed Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Oramed Pharmaceuticals from analyzing Oramed Pharmaceuticals' financial statements. These drivers represent accounts that assess Oramed Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Oramed Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 57.9M | 71.7M | 560.3M | 469.1M | 422.2M | 443.3M | |
| Enterprise Value | 54.6M | 52.4M | 483.6M | 429.6M | 386.6M | 405.9M |
Oramed Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Oramed Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Oramed Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Oramed Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Oramed Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Oramed Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oramed Pharmaceuticals' value.| Shares | Qube Research & Technologies | 2023-12-31 | 86.5 K | D. E. Shaw & Co Lp | 2024-03-31 | 70.5 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 64.2 K | State Street Corporation | 2023-12-31 | 58 K | Susquehanna International Group, Llp | 2023-12-31 | 45.9 K | Lpl Financial Corp | 2023-12-31 | 43.2 K | Jpmorgan Chase & Co | 2023-12-31 | 28.8 K | Pnc Financial Services Group Inc | 2023-12-31 | 26.2 K | Geode Capital Management, Llc | 2023-12-31 | 25.5 K | Murchinson Ltd. | 2023-12-31 | 1.1 M | Bml Capital Management Llc | 2024-03-31 | 844.5 K |
Oramed Fundamentals
| Return On Equity | 0.0648 | ||||
| Return On Asset | -0.0465 | ||||
| Profit Margin | 15.51 % | ||||
| Operating Margin | (20.06) % | ||||
| Current Valuation | (48.66 M) | ||||
| Shares Outstanding | 40.63 M | ||||
| Shares Owned By Insiders | 11.27 % | ||||
| Shares Owned By Institutions | 13.99 % | ||||
| Number Of Shares Shorted | 324.61 K | ||||
| Price To Earning | (11.22) X | ||||
| Price To Book | 0.57 X | ||||
| Price To Sales | 70.76 X | ||||
| Revenue | 2.7 M | ||||
| Gross Profit | 2.7 M | ||||
| EBITDA | (36.98 M) | ||||
| Net Income | (37.76 M) | ||||
| Cash And Equivalents | 133.91 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 894 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.01 X | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (27.92 M) | ||||
| Short Ratio | 3.06 X | ||||
| Earnings Per Share | 0.26 X | ||||
| Target Price | 4.25 | ||||
| Beta | 1.86 | ||||
| Market Capitalization | 96.29 M | ||||
| Total Asset | 161.64 M | ||||
| Retained Earnings | (163.08 M) | ||||
| Working Capital | 109.37 M | ||||
| Current Asset | 31 M | ||||
| Current Liabilities | 4 M | ||||
| Net Asset | 161.64 M |
About Oramed Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oramed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oramed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oramed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Oramed Pharmaceuticals Piotroski F Score and Oramed Pharmaceuticals Altman Z Score analysis. To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Oramed Stock analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Oramed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oramed Pharmaceuticals. If investors know Oramed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oramed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.26 | Revenue Per Share 0.017 | Quarterly Revenue Growth (1.00) | Return On Assets (0.05) | Return On Equity 0.0648 |
The market value of Oramed Pharmaceuticals is measured differently than its book value, which is the value of Oramed that is recorded on the company's balance sheet. Investors also form their own opinion of Oramed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oramed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oramed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oramed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oramed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oramed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.